JAK inhibition for the treatment of rheumatoid arthritis: A new era in oral DMARD therapy

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 961-973

  Vaddi, Kris ^a   Luchi, Monica ^a  

^a Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

Author keywords

IL 6; JAK STAT pathway; Oral DMARD; Rheumatoid arthritis

Indexed keywords

BARICITINIB; CP 550; CP 690; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; JANUS KINASE INHIBITOR; METHOTREXATE; RUXOLITINIB; STAT PROTEIN; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANAPHYLAXIS; CYTOPENIA; DEMYELINATING DISEASE; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; HEART FAILURE; HUMAN; LYMPHOMA; MEDLINE; NEUTROPENIA; PATHOPHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; ENZYME INHIBITORS; HUMANS; JANUS KINASES; MOLECULAR STRUCTURE; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84862276942     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.690029     Document Type: Review

References (51)

1. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2(6):473-88. (Pubitemid 37361728)
2. Klarescog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373(9664):659-72
3. Curtis J, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor a antagonists. Arthritis Rheum 2007;56(4):1125-33 (Pubitemid 46608637)
4. Lipsky PE. Why does rheumatoid arthritis involve the joints? N Engl J Med 2007;356(23):2419-20.
5. Lipsky PE. Rheumatoid arthritis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine. 16th edition. McGraw-Hill; New York: 2005. p. 1968-77
6. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990;33(3):305-15. (Pubitemid 20109181)
7. Maini RN, Feldmann M. Cytokine therapy in rheumatoid arthritis. Lancet 1996;348(9030):824-5.
8. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007;56(12):4226-7 (Pubitemid 350262351)
9. Hetland ML, Christensen IJ, Tarp U, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62(1):22-32
10. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician 2005;72(6):1037-47 (Pubitemid 43093259)
11. Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET trial. J Rheumatol 2011;38(12):2548-56
12. Naka T, Nishimoto N, Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002;4(Suppl 3):S233-42.
13. Fonseca JE, Santos MJ, Canhao H, Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8(7):538-42
14. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010;6(2):189-95
15. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week muticentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67(11):1516-23
16. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97 (Pubitemid 351392039)
17. Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells 1994;12(3):262-77
18. Ihle JN, Witthuhn BA, Quelle FW, et al. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem Sci 1994;19(5):222-7. (Pubitemid 24187246)
19. Ihle JN. The Janus kinase family and signaling through members of the cytokine receptor superfamily. Proc Soc Exp Biol Med 1994;206(3):268-72 (Pubitemid 24241484)
20. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93(3):385-95 (Pubitemid 28232083)
21. Decker T, Meinke A. Jaks, Stats and the immune system. Immunobiology 1997;198(1-3):99-111.
22. Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors-an intimate relationship. Biochem Pharmacol 2006;72(11):1538-46 (Pubitemid 44666728)
23. Yamaoka K, Saharinen P, Pesu M, et al. The Janus kinases (Jaks). Genome Biol 2004;5(12):253.
24. Haque SJ, Sharma P. Interleukins and STAT signaling. Vitam Horm 2006;74:165-206
25. Schindler C, Plumlee C. Inteferons pen the JAK-STAT pathway. Semin Cell Dev Biol 2008;19(4):311-18
26. Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-87.
27. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93(3):373-83 (Pubitemid 28232082)
28. Neubauer H, Cumano A, Muller M, et al. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93(3):397-409 (Pubitemid 28232084)
29. Suzuki K, Nakajima H, Saito Y, et al. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000;12(2):123-32 (Pubitemid 30088304)
30. Shimoda K, Kato K, Aoki K, et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 2000;13(4):561-71
31. Thompson JE, Cubbon RM, Cummings RT, et al. Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett 2002;12(8):1219-23 (Pubitemid 34270567)
32. Tasocitinib. Drugs R D 2010;10(4):271-84.
33. Flanagan ME, Blumenkopf TA, Brissette WH, et al. Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection. J Med Chem 2010;53(24):8468-84
34. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond) 2010;7:41
35. Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol 2011;186(7):4234-43.
36. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010;115(15):3109-17
37. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184(9):5298-307.
38. van Vollenhoven RF, Fleischmann RM, Cohen SB, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, or adalimumab versus placebo in patients with rheumatoid arthritis on background methotrexate: a phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl 10):408
39. Vanhoutte F, Galien R, Vets E, et al. GLPG0634 shows selective inhibition of JAK1 and maintained JAK-STAT suppression in healthy volunteers [abstract]. Arthritis Rheum 2011;63(Suppl 10):2210
40. van der Heijde D Tanaka et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate reduced the progression of structural damage in patients with rheumatoid arthritis: a 24-month phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl 10):2592
41. Burmester G-R, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in combination with methotrexate, in patients with active rheumatoid arthritis with an inadequate response to tumor necrosis factor-inhibitors: a 6-month phase 3 study [abstract]. Arthritis Rheum 2011;63(Suppl 10):718
42. Cohen S, Radominski SC, Asavatanabodee P, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor: analysis of infections and all-cause mortality across phase 3 and long-term extension studies in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2011;63(Suppl 10):409
43. Williams W, Scherle P, Shi J, et al. A randomized, placebo-controlled study of INCB018424, a selective Janus kinase 1 and 2 (Jak 1&2) inhibitor in rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2008;60(Suppl 10):714
44. Greenwald MW, Fidelus-Gort R, Levy R, et al. A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract]. Arthritis Rheum 2010;62(Suppl 10):2172
45. Fleischman R, Spencer-Green GT, Fan F, et al. Dose ranging study of VX-509, an oral selective JAK3 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) [abstract]. Arthritis Rheum 2011;63(Suppl 10):L3
46. Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis 2008;67(7):909-16 (Pubitemid 351956650)
47. Garber K. Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis. Nat Biotechnol 2011;29(6):467-8
48. Wolfe F, Michaud K. Anemia and renal function in patients with rheumatoid arthritis. J Rheumatol 2006;33(8):1516-22 (Pubitemid 44168821)
49. Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009;15(10):1556-61
50. del Rincon I, Freeman GL, Haas RW, et al. Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum 2005;52(11):3413-23 (Pubitemid 41612207)
51. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011;31(4):451-6